Ω-3 polyunsaturated fatty acids and immune-mediated diseases: Inflammatory bowel disease and rheumatoid arthritis

C. Ruggiero, F. Lattanzio, F. Lauretani, B. Gasperini, C. Andres-Lacueva, A. Cherubini

Research output: Contribution to journalArticle

Abstract

Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their anti-inflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohn's disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.

Original languageEnglish
Pages (from-to)4135-4148
Number of pages14
JournalCurrent Pharmaceutical Design
Volume15
Issue number36
DOIs
Publication statusPublished - Dec 2009

Fingerprint

Immune System Diseases
Unsaturated Fatty Acids
Inflammatory Bowel Diseases
Rheumatoid Arthritis
Anti-Inflammatory Agents
Inflammation
Eicosanoids
Fish Oils
Ulcerative Colitis
Arachidonic Acid
Crohn Disease
Sample Size
Reactive Oxygen Species
Mucous Membrane
Joints
Clinical Trials
Cytokines
Pain
Wounds and Injuries
Infection

Keywords

  • Crohn disease
  • Inflammation
  • Inflammatory bowel disease
  • Polyunsaturated fatty acids
  • Reumathoid arthritis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Ω-3 polyunsaturated fatty acids and immune-mediated diseases : Inflammatory bowel disease and rheumatoid arthritis. / Ruggiero, C.; Lattanzio, F.; Lauretani, F.; Gasperini, B.; Andres-Lacueva, C.; Cherubini, A.

In: Current Pharmaceutical Design, Vol. 15, No. 36, 12.2009, p. 4135-4148.

Research output: Contribution to journalArticle

@article{d7effe50e88347b7983d37ebd8e3b802,
title = "Ω-3 polyunsaturated fatty acids and immune-mediated diseases: Inflammatory bowel disease and rheumatoid arthritis",
abstract = "Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their anti-inflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohn's disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.",
keywords = "Crohn disease, Inflammation, Inflammatory bowel disease, Polyunsaturated fatty acids, Reumathoid arthritis, Ulcerative colitis",
author = "C. Ruggiero and F. Lattanzio and F. Lauretani and B. Gasperini and C. Andres-Lacueva and A. Cherubini",
year = "2009",
month = "12",
doi = "10.2174/138161209789909746",
language = "English",
volume = "15",
pages = "4135--4148",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "36",

}

TY - JOUR

T1 - Ω-3 polyunsaturated fatty acids and immune-mediated diseases

T2 - Inflammatory bowel disease and rheumatoid arthritis

AU - Ruggiero, C.

AU - Lattanzio, F.

AU - Lauretani, F.

AU - Gasperini, B.

AU - Andres-Lacueva, C.

AU - Cherubini, A.

PY - 2009/12

Y1 - 2009/12

N2 - Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their anti-inflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohn's disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.

AB - Inflammation is part of the normal host response to infection and injury. However, inappropriate inflammation contributes to several diseases, including inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Both conditions are characterized by the excessive production of inflammatory cytokines, arachidonic acid (AA)-derived eicosanoids, and other inflammatory agents (e.g., reactive oxygen species, adhesion molecules). By virtue of their anti-inflammatory action, ω-3 polyunsaturated fatty acids (PUFA) may be beneficial in inflammatory diseases. A large body of evidence supports a protective effect of ω-3 PUFA in experimental animal and ex-vivo models of Crohn's disease (CD), Ulcerative colitis (UC) and RA. Although fish oil supplementation in patients with IBD results in ω-3 PUFA incorporation into gut mucosal tissue and modification of inflammatory mediator profiles, the evidence of clinical benefits of ω-3 PUFA is weak. On the other hand, more convincing data support the efficacy of ω-3 PUFA in reducing pain, number of tender joints, duration of morning stiffness, use of non-steroidal anti-inflammatory drugs and improving physical performance in RA patients. In both IBD and RA further clinical trials with large sample size are needed to clarify the efficacy of ω-3 PUFA as a treatment.

KW - Crohn disease

KW - Inflammation

KW - Inflammatory bowel disease

KW - Polyunsaturated fatty acids

KW - Reumathoid arthritis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=71849103347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849103347&partnerID=8YFLogxK

U2 - 10.2174/138161209789909746

DO - 10.2174/138161209789909746

M3 - Article

C2 - 20041815

AN - SCOPUS:71849103347

VL - 15

SP - 4135

EP - 4148

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 36

ER -